Bismut subsitrat: Perbedaan antara revisi

Bismut subsitrat
Nama sistematis (IUPAC)
	Bismut(3+) kalium 2-olato-1,2,3-propanetrikarboksilat (1:5:2)
Data klinis
Kat. kehamilan	?
Status hukum	?
Rute	Oral
Pengenal
Nomor CAS	880149-29-1
Kode ATC	A02BX05
PubChem	CID 124490479
DrugBank	DB09275
ChemSpider	32821371
UNII	BQE6KE1T4H
KEGG	D09739
Data kimia
Rumus	C12H8BiK5O14
SMILES	eMolecules & PubChem

Jelajahi riwayat secara interaktif

Revisi selanjutnya →

Konten dihapus Konten ditambahkan

VisualTeks wiki

Sebaris

Revisi per 31 Agustus 2024 10.45

Bismut subsitrat adalah garam bismut yang digunakan dalam kombinasi dengan antibiotik dan penghambat pompa proton untuk pengobatan infeksi akibat bakteri Helicobacter pylori.^[1]^[2]

Kombinasi dosis tetapnya dengan antibiotik metronidazol dan tetrasiklin dijual dengan nama dagang Pylera.^[3]

Efek samping

Interaksi

Farmakologi

Properti kimia

Referensi

^ "P/74/2009: European Medicines Agency decision of 20 April 2009 on the granting of a product specific waiver for Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride (EMEA-000382-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended" (PDF). European Medicines Agency. 2009-06-10. Diarsipkan dari versi asli (PDF) tanggal 2017-10-24. Diakses tanggal 2017-10-24.
^ Urgesi R, Cianci R, Riccioni ME (2012). "Update on triple therapy for eradication of Helicobacter pylori: current status of the art". Clinical and Experimental Gastroenterology. 5: 151–7. doi:10.2147/CEG.S25416 . PMC 3449761 . PMID 23028235.
^ Kesalahan pengutipan: Tag <ref> tidak sah; tidak ditemukan teks untuk ref bernama AC

[1] "P/74/2009: European Medicines Agency decision of 20 April 2009 on the granting of a product specific waiver for Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride (EMEA-000382-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended" (PDF). European Medicines Agency. 2009-06-10. Diarsipkan dari versi asli (PDF) tanggal 2017-10-24. Diakses tanggal 2017-10-24.

[Urgesi2012-2] Urgesi R, Cianci R, Riccioni ME (2012). "Update on triple therapy for eradication of Helicobacter pylori: current status of the art". Clinical and Experimental Gastroenterology. 5: 151–7. doi:10.2147/CEG.S25416 . PMC 3449761 . PMID 23028235.

[AC-3] Kesalahan pengutipan: Tag <ref> tidak sah; tidak ditemukan teks untuk ref bernama AC

[1]

[2]

[3]

@@ Baris 1: / Baris 1: @@
+{{Infobox drug
+| IUPAC_name        =  Bismut(3+) kalium 2-olato-1,2,3-propanetrikarboksilat (1:5:2)
+| image             =
+| alt               =
+| caption           =
+<!-- Clinical data -->
+| pronounce         =
+| tradename         =
+| Drugs.com         =
+| MedlinePlus       =
+| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->
+| pregnancy_AU_comment =
+| pregnancy_US      = <!-- A/B/C/D/X/N -->
+| pregnancy_category=
+| routes_of_administration = Oral
+| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
+| legal_AU_comment =
+| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
+| legal_BR_comment =
+| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_DE = <!-- Anlage I, II, III -->
+| legal_NZ = <!-- Class A, B, C -->
+| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
+| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->
+| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
+| legal_status      = <!-- Free text -->
+<!-- Pharmacokinetic data -->
+| bioavailability   =
+| protein_bound     =
+| metabolism        =
+| metabolites       =
+| onset             =
+| elimination_half-life =
+| duration_of_action =
+| excretion         =
+<!-- Identifiers -->
+| CAS_number        = 880149-29-1
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = BQE6KE1T4H
+| class             =
+| ATCvet            =
+| ATC_prefix        = A02
+| ATC_suffix        = BX05
+| PubChem           = 124490479
+| DrugBank          = DB09275
+| ChemSpiderID      = 32821371
+| KEGG              = D09739
+<!-- Chemical and physical data -->
+| chemical_formula  =
+| C=12 | H=8 | Bi=1 | K=5 | O=14
+| molecular_weight =
+| smiles = C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].[K+].[K+].[K+].[K+].[K+].[Bi+3]
+| StdInChI=
+| StdInChIKey =
+}}
 '''Bismut subsitrat''' adalah garam [[bismut]] yang digunakan dalam kombinasi dengan [[antibiotik]] dan [[penghambat pompa proton]] untuk pengobatan infeksi akibat bakteri ''[[Helicobacter pylori]]''.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500005327.pdf|title=P/74/2009: European Medicines Agency decision of 20 April 2009 on the granting of a product specific waiver for Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride (EMEA-000382-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended|publisher=[[European Medicines Agency]]|date=2009-06-10|access-date=2017-10-24|archive-date=2017-10-24|archive-url=https://web.archive.org/web/20171024205050/http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500005327.pdf|url-status=dead}}</ref><ref name=Urgesi2012>{{cite journal | vauthors = Urgesi R, Cianci R, Riccioni ME | title = Update on triple therapy for eradication of Helicobacter pylori: current status of the art | journal = Clinical and Experimental Gastroenterology | volume = 5 | pages = 151–7 | year = 2012 | pmid = 23028235 | pmc = 3449761 | doi = 10.2147/CEG.S25416 | doi-access = free }}</ref>
 Kombinasi dosis tetapnya dengan antibiotik [[metronidazol]] dan [[tetrasiklin]] dijual dengan nama dagang ''Pylera''.<ref name="AC" />
 ==Efek samping==
 ==Interaksi==